DR-168 Defining mutational signatures of childhood cancer treatments
Numerous environmental triggers have been found to leave a mutational footprint on the DNA of human cancers. In our lab, we want to identify how the treatments of pediatric cancer contribute to the development of second cancers. To robustly link a treatment to a mutational footprint found in pediatric second cancers, we want to investigate the mutations in as many tumors and tumor types that have undergone similar treatment and search for the same signature. Hereby, we identify the treatments with the highest contribution to the development of second cancers, which can be taken into account in new treatment regimens.
Ruben van Boxtel Prinses Maxima Centrum Netherlands
Terug naar nieuwsMeer nieuws
Certificaat databeveiliging vernieuwd
“Binnen alle pijlers in control” zei de beoordelaar bij de controle van onze databeveiliging. In vier dagen is de hele organisatie …
Grote winst te behalen met studies naar DNA-mutaties in lymfeklierkanker
21 januari 2019 Whole Genome Sequencing (WGS) wint terrein in de diagnostiek van solide tumoren. In de hematopathologie blijkt sequencing …
‘Een grote datasnoepwinkel die veel energie geeft aan artsen én onderzoekers’
Harmen van de Werken – Managing Director van het Cancer Computational Biology Center (CCBC) en Universitair Docent Afdeling Urologie van …
Gepersonaliseerde selectie van experimentele behandeling bij patiënten met gevorderde solide kanker is mogelijk met behulp van whole genome sequencing.